ArticleFrontiers in pharmacology2016
Glucagon-Like Peptide-1 Analog, Liraglutide, Delays Onset of Experimental Autoimmune Encephalitis in Lewis Rats.
Article in Frontiers in pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- Glucagon-Like Peptide-1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review.Annals of clinical and translational neurology · 2026Review
- Adjunctive Dulaglutide in Relapsing-Remitting Multiple Sclerosis: A Randomized Open-Label Proof-of-Concept Trial.Neurology and therapy · 2026Article
- The promise of GLP-1 receptor agonists for neurodegenerative diseases.The Journal of clinical investigation · 2026Review
- Leptin as a Potential Modifier of Neuroinflammation: Contrasting Roles in Alzheimer's Disease and Multiple Sclerosis.International journal of molecular sciences · 2025Review
- Incretin-based therapeutics for the treatment of neurodegenerative diseases.Nature metabolism · 2025Review
- Proteomic Profiling and Therapeutic Targeting of Oxidative Stress in Autoimmune Encephalitis.Journal of molecular neuroscience : MN · 2025Article
- Antioxidant Therapies in the Treatment of Multiple Sclerosis.Biomolecules · 2024Review
- The Role of Glucagon-Like Peptide-1 Agonists in the Treatment of Multiple Sclerosis: A Narrative Review.Cureus · 2024Review
- Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database.Therapeutic advances in neurological disorders · 2024Article
- Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.Pharmacological research · 2022Review
- Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases.International journal of molecular sciences · 2022Review
- Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis-related NLRP3 pathway.CNS neuroscience & therapeutics · 2022Article
- Glucagon-Like Peptide-1 Receptor Agonists as Potential Myelination-Inducible and Anti-Demyelinating Remedies.Frontiers in cell and developmental biology · 2022Review
- Liraglutide Improves Cognitive and Neuronal Function in 3-NP Rat Model of Huntington's Disease.Frontiers in pharmacology · 2021Article
- Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer's disease and Parkinson's disease.AMB Express · 2020Article
- Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Article
- Dulaglutide Modulates the Development of Tissue-Infiltrating Th1/Th17 Cells and the Pathogenicity of Encephalitogenic Th1 Cells in the Central Nervous System.International journal of molecular sciences · 2019Article
- Ghrelin Attenuates Neuroinflammation and Demyelination in Experimental Autoimmune Encephalomyelitis Involving NLRP3 Inflammasome Signaling Pathway and Pyroptosis.Frontiers in pharmacology · 2019Article
- Tackling dipeptidyl peptidase IV in neurological disorders.Neural regeneration research · 2018Review
- Detection of Glycan Shedding in the Blood: New Class of Multiple Sclerosis Biomarkers?Frontiers in immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.